Article Text

Download PDFPDF

Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients
  1. Ennio Giulio Favalli1,
  2. Orazio De Lucia1,
  3. Martina Biggioggero1,
  4. Nicoletta Del Papa1,
  5. Roberto Caporali1,2
  1. 1 Division of Clinical Rheumatology, Gaetano Pini-CTO, Milano, Italy
  2. 2 Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milano, Italy
  1. Correspondence to Dr Ennio Giulio Favalli, Division of Clinical Rheumatology, Gaetano Pini-CTO, Milano 20122, Italy; ennio.favalli{at}

Statistics from

The potential role of chloroquine (CQ) and hydroxychloroquine (HCQ) in the management of COVID-19 is certainly of relevance in this health emergency scenario. For this reason, we read with great interest the letter published by Romão and colleagues highlighting the need for more definite evidence on the role of antimalarial drugs in both preventing severe acute respiratory syndrome coronavirus-2 infection and making COVID-19 clinical course milder.1 While several ongoing clinical trials are progressively providing controversial data about the real efficacy and safety of antimalarials in the treatment of overt COVID-19,2–4 rheumatological patients already taking CQ or HCQ for the treatment of chronic inflammatory diseases are an excellent bench for testing the potential effect in preventing the contagion.5 Being operative in the Research Center for Adult and Paediatric Rheumatic Diseases of the ASST Gaetano Pini-CTO in Milan (Lombardy), we had the opportunity to deal with …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles